PDE4A and COVID-19: Moreover, PDE‐4 inhibition has demonstrated promising therapeutic potential in reducing lung fibrosis, improving alveolar integrity and modulating immune cell behaviour, which are relevant in the context of COVID‐19‐related pulmonary complications [9, 10, 11, 12].